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Medication Error Prevention Strategies
in the Pediatric Population
By
Elisabeth Mouw, PharmD
Pharmacy Practice Resident
Pediatric patients often require
medication therapy during their
childhood and require special
consideration because they are at
an increased risk for medicationrelated errors.1-8 Young children
have less developed communication skills compared with adults,
which impedes feedback to
health care professionals about
potential adverse effects or mistakes in medication administration.5 In addition, children are
less likely to ask health care professionals about their care.4
Pediatric patients may be up to
3 times more likely than adult
patients to experience a medication error.2 Pediatric patients are
most likely to experience medication errors due to health care
professionals being unfamiliar
with pediatric dosage forms and
weight-based dosing.2,4
The medication use cycle includes prescribing, transcription,
preparation, dispensing, administration, and monitoring.2 The
most commonly reported errors
are the administration of an in-

correct dose or incorrect frequency, the administration of an
inappropriate medication for the
condition being treated, the prescribing of the wrong route of administration for a medication, and
failure to perform follow-up
monitoring for adverse reactions
and drug interactions.2 The lack
of information regarding pediatric
doses and dosage forms may also
increase the risk of errors.2
Some strategies to help reduce
medication errors include standardizing order forms with
weight-based dosing and allergy
information as required components of the order. Standardizing
weight measurements (ie, only
expressing body weight in kilograms) across the organization
decreases confusion regarding
weight-based dosing.2 MUSC order forms may be accessed at
www.musc.edu/cce/ORDFRMS/.
In addition, by encouraging employees to report errors, more detailed information can be obtained
regarding pediatric medication
errors, and better policies can be
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developed and implemented.2,4,7
Medication errors occurring at
MUSC should be reported on the
Patient Safety Net (PSN) Website
which can be accessed using the
UHC PSN icon located on every
LYNX workstation.
Prescribers should be encouraged
to write legibly using unambiguous language.2,4 Orders for pediatric patients should be written
based on weight, and prescribers
should ensure that the prescribed
dose does not exceed the usual
adult dosage.2 In addition, prescribers should ensure that they
are using the patient’s current
weight when writing orders.2 Because medication errors are most
likely to occur when orders are
written for intravenous fluids, orders should be written to include
dose and volume, as well as quantifying additives per liter, and also
including the rate at which the solution is to be administered.2 All
instructions should be written out
to eliminate confusion and vague
instructions. Institutions should
establish prohibited abbreviations,
and all orders that are written using these abbreviations should be
Prescribers should
clarified.2
avoid the use of terminal and leading zeroes.2 For example, orders
for 5 milligrams of a medication
should be written as 5 milligrams
as opposed to 5.0 milligrams.2
The use of terminal zeros may
lead to a pharmacist misinterpreting the order as 50 milligrams,
resulting in a 10-fold overdose.2
The names of medications should
be spelled out and not abbreviated, and generic names should be
used in place of brand names.2
Physicians should also be required
to print their name along with a
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signature and contact number.2
The MUSC policy regarding
medication orders may be accessed at www.musc.edu/
medcenter/policy/Med/C78.pdf,
and the policy regarding prohibited abbreviations may be accessed at www.musc.edu/
medcenter/policy/Med/C21.pdf.
Pharmacists working in children’s hospitals should ensure
that all medication orders are
written according to organizational guidelines.2,4 Pharmacists
can work with prescribers to
help ensure that all medications
ordered are in an easy-toadminister dosage form and that
there are no cross-sensitivities
with allergies or interactions
with pre-existing medications.2
In addition, all orders requiring
calculations should be rechecked
for accuracy, and all confusing
orders should be clarified.2
Studies have shown that errors
are less likely to occur when a
clinical pharmacist is present on
rounds or is involved in dosing
medications.2,7 Pharmacists can
also be involved with medication
histories and discharge counseling to help ensure that parents
are familiar with pediatric medication administration.2,4,8
Nurses are usually the last step
in the medication use cycle before the medication reaches the
patient. The nursing staff should
be encouraged to recheck all previous calculations and verify all
medication orders before administering medications to the patient.2 In addition, nurses should
frequently consult with parents
to ensure that all questions are
answered regarding medication

therapy.2,4
Technology can play a significant
role in decreasing medication errors. Some examples include computerized prescriber order entry,
computerized medication administration records, automated pharmacy systems, bar-coding,
“smart” intravenous devices, and
computerized discharge prescriptions and instructions.5
Through instituting policies and
procedures, integrating technology
appropriately into the organization, and continued training, medication errors in pediatric patients
can be reduced.

Did You Know...
Acute phosphate nephropathy associated with the use of oral sodium phosphates (OSP) (eg,
Fleet® Phospho-soda®) for bowel
cleansing has been reported by the
Food and Drug Administration.
Individuals at increased risk of
acute phosphate nephropathy include those of advanced age, those
with kidney disease or decreased
intravascular volume, and those
using medications that affect renal
perfusion or function. Use of OSP
in patients with kidney disease,
impaired renal function or perfusion, dehydration, or uncorrected
electrolyte abnormalities should
be avoided. Also, the recommended doses of OSP should not
be exceeded, and the concomitant
use of laxatives containing sodium
phosphate should be avoided. Patients should be adequately hydrated during bowel cleansing,
and baseline and post-procedural
laboratory values should be evaluated in patients at risk for serious
adverse events.
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Prescribing Restricted
Formulary Medications:
How You Can Help Us
Help You
The Pharmacy and Therapeutics
Committee recently approved
standardized scripting for physicians to use when writing orders
for restricted formulary medications.
By using standardized
wording, physicians will improve
the efficiency with which a pharmacist can process an order for a
restricted medication. Scripting of
orders for restricted formulary
medications will also assist the
pharmacist processing the order to
determine whether the intent of
the restriction is met. An additional benefit is that fewer telephone calls will be made by pharmacists to physicians for order
clarification. The following examples illustrate the use of scripting
orders for restricted formulary
medications. Approved scripting
appears in boldface.
An internal medicine physician
(Dr. Barton) wants to prescribe
linezolid for a patient on 8 West.
The formulary restriction on linezolid specifies that when it is used
outside of an intensive care unit, a
consult must be obtained from an
attending or fellow on the infectious diseases service. The order
that Dr. Barton writes is as follows: linezolid 600 mg, IV,
Q12H, verbal approval obtained
from Dr. Cantey on ID Consult
Service concerning formulary
restriction.
A pediatrician (Dr. Noyes) wants
to prescribe meropenem for a pediatric patient who weighs 22
kilograms. The formulary restrict-
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ion on meropenem specifies that
this agent may be used in patients with cystic fibrosis. The
order that Dr. Noyes writes is as
follows: meropenem 440 mg,
IV, Q8H (60 mg/kg/day), patient has cystic fibrosis concerning formulary restriction.
Physicians who prescribe restricted formulary medications
are asked to use the approved
scripting. The Medical Center
Formulary System Policy C-82
has been revised to reflect this
practice. Formulary restrictions
are noted in the electronic formulary, and an alphabetic listing
is available at www.musc.edu/
pharmacyservices/DI/
restricts.pdf.

Dexmedetomidine
Dexmedetomidine (Precedex®),
is a relatively selective alpha2
agonist with sedative properties.
This medication is significantly
more costly than similar alternatives (eg, propofol, midazolam).
An interdisciplinary group was
convened to develop guidelines
for appropriate use of dexmedetomidine. The group was led by
Holly MacFall, PharmD, and
consisted of Alice Boylan, MD;
Julio Chalela, MD; Jack Crumbley, MD; and Susan Harvey,
MD. Frank Mielck, MD; Joel
Cochran, MD; Fred Tecklenburg, MD; and Sally Webb, MD,
were also consulted during the
development of the guidelines.
The guidelines are printed on
page 4 and are posted online at
w w w m u s c . e d u /
pharmacyservices/medusepol/
DexmedetomidineGL.pdf.

Formulary Update
The Pharmacy and Therapeutics
Committee recently approved the
following actions that became effective May 15, 2006:
Additions:
Acamprosate (Campral®)
333-mg enteric-coated tablets
Additions with Restriction:
Suboxone®
2/0.5- and 8/2-mg sublingual
tablets
Palifermin (Kepivance™)
6.25-mg vials
Deletions:
Urokinase (Abbokinase®)
9000- and 250,000-IU injections
Streptokinase (Streptase®)
250,000-, 750,000-, and
1,500,000-IU injections
Lipisorb® nutritional supplement
8-oz cans
Vasocon-A®
0.5-oz ophthalmic drops
Accuzyme® Spray
33-mL bottles
Line Extentions:
Risperidone (Risperdal® M-Tab®)
3- and 4-mg orally disintegrating tablets
Accuzyme® Ointment
6- and 30-g tubes
Temporary Product
Replacement:
Perflutren lipid microspheres
(Definity®)
2-mL vial
Change in Restriction:
Dexmedetomidine (Precedex®)
2-mL vials [100 micrograms/mL]
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MUSC Dexmedetomidine (Precedex®) Guidelines for Use
Restrictions
Prescribing is restricted to physicians with deep sedation privileges or attending-level physicians and fellows
practicing in a critical care setting or anesthesiology.
Dosing Guidelines and Indications
Dexmedetomidine may be used for the following indications in adult patients, for no greater than 24 hours.1
Generally initiate a loading dose of 1 microgram/kg over 10 to 30 minutes (consider longer load [ie, 30 minutes] for patients ≥ 65 years of age).
A loading dose should be followed by a maintenance infusion of 0.2 to 0.7 micrograms/kg/hr.
Dose reductions should be considered in patients with renal or hepatic impairment.
‡

Sedation of initially intubated and/or mechanically ventilated adult patients in the ED, OR, or
ICU with an absolute or relative contraindication to propofol, benzodiazepines, and/or opioids
(eg, hypersensitivity, hypertriglyceridemia) 1

‡

Awake craniotomy in adult patients 2-8

‡

Extubation of ICU and post-operative adult inpatients in an ICU or PACU when unable to wean
using propofol, benzodiazepines, or opioids or when they are contraindicated 9-19
₤

Sedation prior to ECT in adult patients with a history of postictal agitation 20

‡

Intubated and nonintubated adult neurology patients, in an ICU, requiring sedation and frequent neuroassessment when other short-acting titratable sedatives are contraindicated or ineffective 8, 13, 21-25
‡

Awake fiberoptic intubation 26-29 or ₤bronchoscopy in adult patients with difficult airways whose
comorbidities may increase risk for developing hypoxemia and/or hypercapnia during intubation
and/or patients in which hypoxemia and/or hypercapnia could significantly increase morbidity or
mortality (eg, head trauma, history of sleep apnea, morbid obesity)
‡

Bariatric surgery in adult patients (immediate postoperative period only) 30-37

‡

Sedation or agitation in pediatric patients in an ED, OR, PACU, ICU, or radiology with an absolute or relative contraindication to propofol, benzodiazepines, chloral hydrate, and/or ketamine
(eg, hypersensitivity, sedation failure, respiratory depression, paradoxic agitation) provided appropriate monitoring is in place 38-40

‡
₤

Literature to support dexmedetomidine use
Lack of literature to support dexmedetomidine use

Monitoring Parameters
Level of sedation using SAS
Blood pressure every 5 minutes for first 30 minutes, then every 15 minutes
Heart rate
Continuous oximetry
Telemetry
Renal function
References available upon request

